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Human herpesvirus 8 (HHV-8) is the causative agent of Kaposi’s sarcoma- a cancerous 
tumor of endothelial origin. Development of KS among men who have sex with men (MSM) is 
preceded by viral reactivation as determined by increasing viral antibody levels and viral load in 
circulating immune cells.  Thus, prevention of viral reactivation should result in decreased KS 
incidence. 
HHV-8 infection rates are not significantly different between men and women, yet the 
occurrence of KS is dramatically different between genders.  The prevalence of KS in MSM (15-
60%) is more frequent than that of heterosexual men (0-9%), and occurs even less frequently 
(<1%) in the female population. Males are approximately around 13 times more likely to develop 
KS than women. This strong sexual bias brings up several possible factors that may explain the 
disparity between KS development and HHV-8 infection rates between men and women. Two of 
these factors are: First, a more robust natural immune response occurs in women following a 
primary infection, resulting in higher viral antibody titers. The presence of higher viral antibody 
titers may control viral reactivation, thus reducing the risk of KS development.  Second, there may 
be a hormonal regulation of viral reactivation.  Our laboratory has found the presence of functional 
estrogen response elements in the HHV-8 genome and preliminary results suggest that in the 
presence of estrogen, spontaneous reactivation of HHV-8 in B cells is reduced.  Prevention of viral 
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reactivation would decrease KS development and in this hypothesis, viral antibody titers would be 
decreased among women due to the lack of viral reactivation (compared to men).  In addition, 
increased viral reactivation among men may result in increased levels of proinflammatory 
cytokines, which would further modulate their immune response. 
To test the hypotheses that men and women mount differing immune responses to HHV-8 
infection, HHV-8 antibody titers were determined in cohorts of men and women at risk 
of developing KS.  Circulating proinflammatory cytokine profiles were also analyzed 
between HHV-8 infected males and females to determine if levels of proinflammatory 
cytokines differ between genders. It is hypothesized that women will have a more robust 
immune response resulting in fewer viral reactivation events while men, due to a lessened 
immune response will reactivate more frequently, and as a result will have higher levels of 
proinflammatory cytokines compared to women. The public health significance of this thesis is 
in regards to more effective treatments to combat or suppress KS development in males.  
v 
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1.0  INTRODUCTION 
1.1 HUMAN HERPESVIRUS-8 
Herpesviruses are a family of double stranded DNA viruses that are prevalent in most 
animal species (1, 2) Over 130 herpesviruses have been identified, eight of which infect humans 
(1). One of these viruses is human herpesvirus 8 (HHV-8). HHV-8 is part of the gamma 
herpesvirus family of DNA tumor viruses (3). HHV-8 was discovered as the etiologic agent of 
Kaposi’s sarcoma in 1994 by Chang and coworkers (4). 
 
Its genome is 160 kb and contains a diverse set of genes that regulate signaling, 
transformation, and extensive immune evasion (5). Like all herpesviruses, HHV-8 establishes 
lifelong latency in its host, with intermittent periods of lytic replication (3). This herpesvirus has 
the ability to induce neoplasia in its hosts, and is also associated with different types of 
malignancies and lymphoproliferative diseases of B cells (3). Specifically, HHV-8 is associated 
with several diseases, such as primary effusion lymphoma (PEL), some forms of multicentric 
Castleman’s disease (MCD), and Kaposi’s sarcoma (KS) (6, 7, 8, 9).  
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1.2 HUMAN HERPESVIRUS-8 GENOME AND REPLICATION  
The HHV-8 genome is 165kb, and contains over 90 ORF’s, at least 11 of which are 
homologs to cellular proteins involved in signal transduction, cell cycle regulation, inhibition of 
apoptosis, and immune modulation (5, 10, 11). HHV-8 genes contain an upstream promoter, 
regulatory sequence, and initiation site, which is followed by a 5’ nontranslated sequence, the ORF 
itself, followed by 3’ nontranslated regions, and finally a polyadenylation signal (1). The coding 
region of the HHV-8 genome is flanked by high GC multiple terminal repeat units of 801 base 
pairs (12, 13). The coding region is a long unique region (LUR) that encodes the approximate 90 
genes (14). HHV-8 dedicates large amounts of coding region in order to produce proteins that are 
able to evade and downregulate the host’s immune system (15). These mechanisms interfere with 
both innate and adaptive immune responses. Some of these genes include viral IL-6, macrophage 
inflammatory proteins 1-3 (MIP), and various chemokines (1, 13, 14). HHV-8 can alter the 
immune environment of the host by blocking apoptosis, decreasing MHC class I surface 
expression, and altering interferon pathways (1, 16). HHV-8 encodes several glycoproteins 
expressed in the virion, including gB, gH, gL, gM, and gN (17). 
1.2.1 Latency  
During latency, HHV-8 infected cells are non-permissive for replication (6, 18). Only some 
viral genes are expressed, encoding proteins only necessary for maintaining the virus within the 
host where it exists as a covalently closed circular episome (19, 20). Viral structural proteins are 
not expressed, and no progeny virus are produced (3). HHV-8 has incorporated several cellular 
genes, most likely during the evolutionary development of the virus. These homologous genes are 
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able to facilitate virus replication, transformation, and survival (14, 21). Latency is essential to the 
pathogenesis of HHV-8, and the majority of cancerous KS cells are latently infected with the virus 
(1). 
1.2.2 Lytic Replication  
During lytic replication, all ORF’s of the viral genome are expressed, which leads to 
successful viral replication, cell lysis, and subsequent cell death (1). Both latent and lytic HHV-8 
genes are felt to contribute to viral oncogenesis (6). This process is facilitated via transformation, 
which has the ability to cause normal cells to proliferate in an uncontrolled manner (21). The 
infection of B-cells is a necessary step in KS development, as HHV-8 infection develops from 
latently infected B-cells (22). Rappocciolo et al. described this by demonstrating that activated B-
cells cannot only be infected with HHV-8, but can produce infectious virus (23). 
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1.3 HHV-8 BINDING AND ENTRY RECEPTORS 
HHV-8 requires two separate receptors: (1) binding receptors and (2) entry receptors, in 
order to infected cells. HHV-8 subunits must first attach to the binding receptor, which then may 
interact with the entry receptor, allowing penetration of the virion into the cell. 
 
In order for HHV-8 to enter a host cell, the viral envelope glycoproteins and other cell 
membrane components must interact according to the following steps: First, the virus must bind 
and attach to the cell surface, interact with a specific entry receptor, and enter the host cell via 
mechanisms such as endocytosis or membrane fusion (1, 76). HHV-8 is then able to release its 
capsid into the cytoplasm of the host cell, post cell fusion (76). Binding receptors are also required 
for proper entry into the host cells by HHV-8, but are not sufficient for entry (2). The interaction 
between glycoproteins and binding receptors tethers the virion to the host cell surface, and then 
the virus is able to interact with entry receptors (2, 76).  
 
1.3.1 Heparin Sulfate 
Heparin sulfate (HS) is “ubiquitous cell surface” molecule, which can bind to a variety of 
ligands and is important for many cellular activities (24). HS is a binding receptor for HHV-8 on 
target cells, and has been shown to bind both glycoproteins (gp)K8.1 and gB (24). K8.1 is present 
in two forms- K8.1A or K8.1B, and both are an integral part of the HHV-8 viral envelope (25).  
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Nelpel et al. demonstrated that K8.1 is capable of binding to heparin sulfate on the surface 
of cells, but is not capable of entering cells through this mechanism. It is believed that K8.1 is one 
of the proteins involved in this complex process. 
 
1.3.2 Integrin α3β1–like (CD 49c/29) 
Integrins are heterodimeric receptors that contain α and β glycoproteins (24).  Chandran et 
al. demonstrated that RGD (Arg-Gly-Asp) amino acids are capable of binding to integrin α3β1–
like (CD 49c/29). The group analyzed the amino acid sequence of HHV-8 glycoproteins, and 
determined that gB contains the RGD motif, and is also capable of entering target cells via this 
mechanism. This group also demonstrated the ability of gB to interact with α3β1. It has been 
established that α3β1 integrin is a cellular receptor for HHV-8 infection.   
 
1.3.3 xCT 
xCT is an amino acid transporter and HHV-8 entry receptor (26). It is one of four known 
HHV-8 entry receptors, and is present on macrophages, and endothelial cells. Parsons et al. 
determined that expression of the entry receptor xCT significantly increases as an individual 
develops KS. This suggests that increased xCT expression increases cell permissiveness for HHV-
8 to enter more cells, and the specificity of xCT expression on varying cell types (26). This may 
make xCT an ideal target for treatment or prevention of developing KS (27). 
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1.3.4 EPHRIN 
Recently, Boshoff et al. reported that the ephrin receptor A2 (EphA2), which is a tyrosine 
kinase, is able to bind to HHV-8 glycoproteins (specifically gH and gL), which allows the virus to 
enter target cells effectively, particularly endothelial cells (28). Upon phosphorylation, EphA2 is 
capable of promoting endocytosis of the host cell, giving this receptor an important role in the 
infection of cells. Like xCT, possible therapies for HHV-8 infection could be blocking this receptor 
as a therapeutic strategy to decrease ongoing lytic infection of cells, which has been demonstrated 
to lead to angiogenesis, and increasing inflammation in the host (28).  
 
1.3.5 DC-SIGN 
DC-SIGN, or Dendritic Cell-Specific Intracellular adhesion molecule 3-Grabbing Non-
integrin, is a C-type lectin receptor that is present on DCs as well as activated macrophages (29). 
The DC-SIGN receptor present on macrophages can bind mannose-type carbohydrates (PAMPS) 
that are found on viruses and other pathogens. DC-SIGN on DCs mediates interactions with 
endothelium, activation of CD4 T-cells, etc. Rappocciolo and colleagues have demonstrated that 
DC-SIGN is a cellular entry receptor for HHV-8 on DC’s, macrophages, and activated B-cells (29, 
30). In vivo, these are the typical cell types that are “natural targets” for HHV-8 entry (17). Hensler 
et al. demonstrated that soluble gB is able to bind DC-SIGN (17). 
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1.4 KAPOSI’S SARCOMA 
KS is a cancerous tumor of endothelial origin (14) and is composed of a mixture of 
irregularly shaped, round capillaries, and spindle-shaped cells often with infiltrating mononuclear 
cells (1, 14). KS usually presents with pigmented skin lesions, which can eventually lead to more 
serious ulcerating tumors (14). Risk factors for the development of KS in HHV-8 infected 
individuals include increased HHV-8 viral load, HIV seropositivity, and immunosuppression (31). 
In order for KS to develop, the virus needs to efficiently establish a persistent infection in the host 
(15).  
The detection of HHV-8 infection in an individual is most often based on the presence of 
antibodies against either lytic or latent viral antigens (14, 31). DNA sequences of HHV-8 have 
been detected in all forms of KS tumors, but can also be detected via PCR from PBMCs (peripheral 
blood mononuclear cells) and BCBLs (body cavity based lymphoma) of both KS subjects, and 
otherwise healthy individuals (32, 33, 34). However, PCR methods can be time consuming, 
expensive, and not as sensitive as serological assays (1). For this reason, testing for specific 
antibodies to HHV-8 is a less expensive and simpler way to determine infection.  Current methods 
for detection of HHV-8 antibodies include enzyme-linked immunosorbant assay (ELISA), western 
blot, and immunofluorescent assay (IFA) (1, 35).   
 
The outbreak of KS in the early 1980’s led in part to the discovery of AIDS.  KS is one of 
the most common AIDS-associated malignancies in the population (31) (Figure 1). Though HHV-
8 infection is evenly distributed throughout the population, prevalence of KS is not evenly 
distributed (36, 37). The prevalence of KS in homosexual men (15-60%) is much more frequent 
than that of heterosexual men (0-9%), and occurs even less frequently in the female population 
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(38). Males are around 13 times more likely to develop KS versus women (2, 3). There are 4 forms 
of KS (3). 
 
 
 (A), Incidence of Kaposi’s sarcoma (KS) in the male population, age-standardized. (B) 
Seroprevalence of HHV-8, compiled from multiple studies. (Figure reprinted with permission 
from Mesri, E. A., E. Cesarman, et al. (2010). “Kaposi’s sarcoma and its associated 
herpesvirus.” Nat Rev Cancer 10(10): 707-719). 
Figure 1 Seroprevalence of HHV-8 versus Seroprevalence of KS.  
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 1.4.1 Classical Kaposi’s sarcoma 
Classical KS is mainly associated with elderly men in Mediterranean countries, and is also 
known as sporadic KS (2, 3). The most common countries associated with this form of KS are 
Italy and Israel. Classical KS is usually nonaggressive, and is often associated with lesions on the 
lower extremities (40). Generally, the older the subjects are, the faster the disease progression (14, 
3).  
 
1.4.2 Endemic Kaposi’s sarcoma 
Endemic KS was discovered in Africa prior to the onset of the AIDS epidemic (42). It is 
found in both men and women, and most notably, young children. This form of KS tends to be 
more aggressive than classical KS, and can affect parts of the body like the lymph nodes. Endemic 
KS is the leading cause of cancer in children in sub-Saharan Africa (40). 
 
1.4.3 Iatrogenic Kaposi’s sarcoma 
Iatrogenic KS is transplant-associated, due to treatment with immunosuppressants (3). It 
normally occurs in subjects after solid-organ transplants that were subsequently treated with 
immunosuppressive drugs to combat organ rejection (2, 7). Withdrawal of therapy can sometimes 
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lead to KS regression. Iatrogenic KS often has a most rapid disease progression compared to 
classical KS, but it is also able to present as a chronic infection as well (14) 
1.4.4 AIDS-Associated Kaposi’s sarcoma 
AIDS-associated KS is the most aggressive form of KS (43). The disease is often associated 
with a high tumor burden and rapid disease course, which is very different from the timecourse of 
infection seen in non-AIDS subjects (6, 44,). AIDS-associated KS involves not only the lower 
extremities and skin, but also the upper body, lymph nodes, and head (7). It may also disseminate 
to other organs such as the lungs, liver, spleen, and GI tract (14). In the 1980’s, individuals with 
AIDS have a 50% lifetime rate of developing KS, however this percentage has declined since 
antiretroviral drugs were introduced (14, 6).  
 
1.4.5 Development and Distribution of Kaposi’s sarcoma 
The distribution of KS is not evenly distributed throughout the population. KS development 
only occurs in a small proportion of the HHV-8 population, and only after a long viral latency 
period (5, 47). The development of KS is dependent on several factors, including the host’s 
underlying immune status, HHV-8 viral titers, HIV coinfection, and immunosuppression (5, 48, 
49). The prevalence of KS does not match with HHV-8 seroprevalence (which is much more 
evenly distributed amongst sexes). This leads us to believe that women are somehow protected 
against developing the cancer. 
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The higher prevalence of KS in men versus women begs the question as to why there is 
such a strong sex bias between sexes. This study has suggested two possible factors that could be 
influencing this bias: 
(1) A more robust humoral response in women (As measured by a higher viral titer 
compared to men): 
 Could decrease the chances of reactivation and developing KS versus men 
due to a stronger immune response to HHV-8. 
 May correlate with higher proinflammatory cytokines in women. 
1.5 ANTIBODIES 
Antibodies and neutralizing antibodies are an integral part of the humoral immune response 
against viral infection. The immune system uses antibodies to identify and neutralize pathogens, 
such as HHV-8 by recognizing antigens, and targeting a specific epitope for each pathogen. They 
have been implicated in controlling the progression of herpesvirus-associated diseases (57, 58). If 
women are capable of eliciting a stronger initial immune response to HHV-8 versus men, this 
would result in higher antibody titers. Higher antibody titers in females may be able to effectively 
combat and suppress reactivation of HHV-8 over time, while males are at a higher risk of 
reactivation, due to a less robust immune response. The role of neutralizing antibodies in 
controlling KS infection is not yet clear. Previous studies have detected the presence of nAb in 
HHV-8 infected individuals, and examined the ability of HHV-8 to inhibit the nAb response 
against infection. Wood et al. found that the total level of antibodies and neutralizing antibodies 
was significantly higher in KS subjects. Kimball et al. examined inhibition of HHV-8 viremia at 
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1:10 or 1:50 dilutions of seropositive subject samples, which was not seen in the seronegative 
subjects (59). Several other research groups such as Ledgerwood et al. and Moss et al. have 
examined virus neutralization based on flow cytometry methods, however no group to date has 
explored this technique with HHV-8 (60). In this study, a GFP expressing virus, BAC16, was used 
to examine the level of neutralizing antibodies in males versus females.  
1.6 THE BAC16 VIRUS 
BAC16 was generated by the J. Jung laboratory, and is a KSHV bacterial artificial 
chromosome (BAC) clone that is derived from the rKSHV.219 virus. It contains the BAC16 
bacmid, which consists of a full-length KSHV genome and GFP under the control of the EF1α 
promoter. This bacmid was transfected into the KS cell line, iSLK. SLK cells were originally 
isolated in Israel in 1990 from a tumor biopsy of the oral mucosa of an immunosuppressed HIV-1 
subject (62). iSLK stands for inducible SLK cells.  They contain the KSHV RTA (replication and 
transcription activator) gene (ORF50), under the control of doxycycline.  The RTA protein is 
necessary and sufficient to reactivate the switch from latency to lytic replication (61, 62). The 
BAC16 virus can be reactivated to productive replication by treating iSLK cells with doxycycline 
for three days. 
 (2) Sex hormone (estrogen) that limits viral reactivation in women (Resulting in lower viral 
titers compared to men): 
 Estrogen may be decreasing HHV-8 replication, which may suppress KS 
reactivation in women. 
 May correlate with lower proinflammatory cytokines in women.  
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 1.7 ESTROGEN 
Estrogen plays an important role in many biological functions, and is mediated by the 
estrogen receptor (ER) (53). ER’s are ligand-dependent transcription factors that are able to bind 
to specific DNA sequences within the promoter of a gene (estrogen response elements) to activate 
gene expression. ER’s bind with high affinity to ERE’s and are widely expressed in different tissue 
types (54). There are 2 subtypes of estrogen receptors- ERα and ERβ, both of which are expressed 
in vascular endothelial cells, smooth muscle cells, and myocardial cells (54, 55). However both 
receptors are functionally distinct and differ in some tissue distribution, DNA-binding domains, 
and activation of estrogen promoters (52). Estrogen is known to participate in the regulation of 
several genes that are involved in proliferative vascular diseases, specifically their pathogenesis. 
This may be due to cell-cell communications, regulation of inflammatory genes, etc. (52, 56). It is 
hypothesized that estrogen may exhibit a protective effect on certain neovascular disorders, such 
as KS due to altering vascular effects such as vascular relaxation and vasodialation, which may 
reduce progression of the lesions (52).  
 
Previous research in the Jenkins’ laboratory has shown that estrogen response elements 
(ERE’s) can be found in front of several HHV-8 genes, which are able to bind estrogen receptor 
proteins, and that these ERE’s appear to be functional in modulating HHV-8 transcription (Patrick 
Shea). Also, that estrogen can induce transcription of some HHV-8 genes, and in the presence of 
estrogen, there is an increase in transcription of HHV-8 genes with ERE’s in proximity to their 
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promoters (Rebeca Compaore- a previous MS student in the Jenkins’ lab). Preliminary research 
has also shown that in the presence of estrogen, HHV-8 does not reactivate in vitro. 
 
1.8 PROINFLAMMATORY CYTOKINES 
Cytokines are hormonal, intra- and inter-cellular messengers that are responsible for many 
biological effects in the immune system including immune cell attraction, activation of humoral 
and cell-mediated immunity and modulation of specific immune responses (64). They are small 
nonstructural proteins with molecular weights ranging from 8 – 40,000 d (64). Most  nucleated 
cells are capable of synthesizing cytokines, and they are also capable of responding to specific 
cytokines, depending on whether or not they express the appropriate receptor (64). Some of the 
major producers of cytokines include B and T-cells, DCs, macrophages, epithelial cells and 
endothelial cells. Cytokines are a very diverse group of messengers, and can contribute to 
stimulating the production of cells, growth and differentiation of cells (developmental processes), 
regulating the immune system, etc. (65).  Cytokines can be divided into proinflammatory and anti-
inflammatory cytokines. The primary role of anti-inflammatory cytokines is to reduce 
inflammation and promote healing of the host. Alternatively, proinflammatory cytokines 
essentially promote disease progression by increasing inflammation in the host (64). For this study, 
proinflammatory cytokines will be the main focus of analysis.  
 
KS is an “inflammatory cytokine-mediated angioproliferative disease” (2). Specifically, 
KSHV has an ORF (K14) that is homologous to cellular OX2- which stimulates primary 
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monocytes, macrophages, and dendritic cells to produce excessive amounts of proinflammatory 
cytokines, such as IL-1β, 7, and TNF- α (66). This means that KS has a strong ability to induce 
inflammation, and promote cytokine-mediated angiogenic proliferation of infected cells (67, 66). 
Excessive levels of proinflammatory cytokines can lead to uncontrolled tissue damage, and 
progression of diseases (68). Previous research has demonstrated that HHV-8 infected endothelial 
cells are driven to proliferate by proinflammatory factors, and that there is an abnormal excess of 
cytokines and chemokines produced by B-cells infected with HHV-8 (65). 
 
HHV-8 infection is able to trigger the release of proinflammatory cytokines that can alter 
the maturation of human cells. Specifically, IL-6 and TNF-α were increased after HHV-8 infection 
of DCs (69). However, this has not been examined in regards to reactivation. HHV-8 binding and 
entering into cells can cause the release of cytokines and chemokines (69). Cytokines also have 
the ability to prevent differentiation of cells in to DCs, decrease antigen uptake and presentation 
to combat infection, and even alter cell surface marker phenotypes (70). Chung et al. reported that 
KS appears to be a hyperplastic disorder that is caused in part by the local production of 
inflammatory cytokines, specifically IL-1, IL-6, and TNF-α. The researchers supported this 
conclusion by demonstrating that the infiltration of inflammatory cells in KS lesions preceded the 
transformation of spindle-shaped endothelial cells. They also reported that the production of these 
inflammatory cytokines are responsible for the activation of vessels and endothelial cells, which 
has the ability to increase adhesiveness, and the recruitment of more immune cells to the site, thus 
increasing inflammation. (66). Finally, cytokines have the ability to polarize DCs to promote a 
Th2 vs. Th1 immune response. Specifically, certain cytokines have the ability to polarize DC’s 
towards the induction of a Th2 response, which can contribute to the persistence of HHV-8 (69). 
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Th1 cells are an essential component of the immune system, specifically the adaptive immune 
response. Th1 cells activate macrophages, and are important for cell-mediated immune response 
to pathogens. They are also important for the activation of CTLs. Th2 cells produce IL-4, 5, 10, 
and 13, which are important in antibody responses and production. Th2 cells also activate 
granulocytes (70). 
 
Because KS has the ability to stimulate cells to produce large amounts of proinflammatory 
cytokines, altering the maturation of different cell types, examining cytokine profiles of males 
versus females would also be an important step in understanding more about the variances in 
immune system regulation between sexes. This study examined 10 different proinflammatory 
cytokines between males and females to determine if there were differences in the subject’s sera 
samples. Differences could indicate disease progression in males if proinflammatory cytokines are 
increased in this population. The 10 cytokines examined were:  
 
1.8.1 IFN-γ 
Interferon gamma is the main Th1 cytokine, and it is a cytokine that produces a 
proinflammatory response that is responsible for killing intracellular pathogens (68). Specifically, 
IFN-γ activates macrophages, has the ability to inhibit viral replication, and can increase CD8+ 
activity (64, 66) Other functions of IFN-γ include increasing antigen presentation, inducing 
production of IgG from B-cells, and suppresses Th2 differentiation (67). This cytokine is produced 
by lymphocytes, and is involved in numerous pathways for a number of medical disorders (64). 
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1.8.2 IL-1β 
Interleukin-1β is a proinflammatory cytokine that was originally referred to as a 
lymphocyte-activating factor (LAF), is produced by activated macrophages, and is an important 
component in the inflammatory response (64, 66). IL-1β is involved in several activities such as 
cell differentiation, proliferation, and cell death of B and T-cells. This cytokine is also involved in 
the induction of prostaglandins, which is a mediator of many biological conditions such as 
regulating hormones, controlling growth of immune cells, and causing vasodialation (68). 
 
 
1.8.3 IL-10 
Interleukin 10 is an anti-inflammatory cytokine that downregulates Th1 cytokines, and co-
stimulatory molecules present on macrophages (66). IL-10 can also increase B-cell survival and 
growth, and may be capable of inhibiting other proinflammatory cytokines, such as those 
mentioned above (68). This cytokine is also capable of inhibiting the synthesis of certain cytokines, 
such as interferons, I2, and 3, which suppress Th1 proinflammatory responses (67) 
 
1.8.4 IL-12p70 
Interleukin 12 production favors the generation of Th1 cells, and is produced by DC’s, B-
cells, and macrophages (67). Specifically, IL-12 is an important component in differentiating naïve 
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T-cells into Th1 cells, and to promote NK cells to stimulate IFN-γ (68). It also has the ability to 
stimulate other cytokines like IFN-γ and TNF-α. IL-12 is able to mediate cytotoxic activity of other 
cell types, and unlike IL-8, is anti-angiogenic (64). IL-12 is encoded by two separate genes- IL-
12A (p35) and IL-12B (p40). IL-12p70 is the homodimer of these two submits (64). Recently, 
there has been discussion as to if IL-12 may be a useful component in some anti-cancer therapies.  
 
1.8.5 IL-13 
Interleukin 13 behaves similarly to IL-4- favoring the generation of Th2 cell stimulation 
and growth. IL-13 has been determined to induce changes in hematopoetic cells, B-cell maturation, 
and differentiation. IL-13 triggers macrophage activity, increasing proinflammatory activity (68). 
 
1.8.6 IL-2 
Interleukin 2 is also known as T-cell growth factor, and stimulates the proliferation of T-
cells. IL-2 is necessary for the differentiation, and growth of T-cells (69). When an antigen binds 
to a TCR, IL-2 secretion is stimulated. IL-2 production levels are associated with diseases such as 
HIV infection, which is an important confounding factor in our study that will be explored later 
(69). 
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1.8.7 IL-4 
Interleukin 4 is also known as B-cell stimulatory factor, and lymphocyte stimulatory factor. 
This cytokine is produced by Th2 cells, and can help activate B-cells, stimulate DNA synthesis, 
and is associated with the promotion of IgE and eosinophilic responses (68). IL-4 production also 
favors the generation of Th2 cells, including their stimulation and growth. Some of the biological 
functions of IL-4 include T-cell proliferation, plasma cell development, and decreased production 
of Th1 cells (68). 
 
1.8.8 IL-6 
Interleukin 6 is another B-cell stimulatory factor, as well as a cytotoxic T-lymphocyte 
(CTL) differentiation factor. IL-6 is very important in inducing inflammation and apoptosis in 
humans (63). It is released from many cell types, and plays an important role in differentiating B-
cells into Ig secreting cells (64, 66) 
 
1.8.9 IL-8 
Interleukin 8 is a chemokine that is produced by macrophages, epithelial, and endothelial 
cells. IL-8 not only induces chemotaxis in target cells, but also causes other cells to migrate 
towards the site of infection (66). It can also induce phagocytosis, and angiogenesis. IL-8 is highly 
associated with inflammation, and is increased by oxidative stress (63, 64). 
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1.8.10 TNF-α 
Tumor necrosis factor alpha is a cytokine that is highly involved in inflammation, and 
mainly produced by activated macrophages, CD4 cells, and NK cells (68). TNF-α is an immune 
regulator, and is able to induce cell death and inflammation in some tumor cell lines (66). TNF-α 
is capable of stimulating IL-1, IL-12, and can induce sepsis and inflammation (67, 68). 
 
 20 
2.0   SPECIFIC AIMS 
This study examined two possible reasons why women are protected against KS 
development, and men are at a much higher risk of developing the disease, regardless of HHV-8 
seroprevalence. The first hypothesis is that there is a more robust humoral response in women, 
which we suspect would result in higher antibody titers versus males. This would allow women to 
mount a stronger immune response to HHV-8, and become more protected against reactivation of 
the virus and development of KS. The second hypothesis involves hormonal control of HHV-8, 
which may be interfering with viral reactivation and therefore suppressing the development of KS 
in women. If this hypothesis is correct, we would expect male antibody titers would be increased 
due to increased reactivation events resulting in their predisposition to develop KS much more 
frequently compared to females. It is also hypothesized that males will have increased levels of 
proinflammatory cytokines versus females, due to increased viral reactivation. Two specific aims 
will be completed to examine each of these hypotheses: 
 
 
AIM 1: Determine HHV-8 antibody titers in a cross-sectional study between MSM in the 
Multicenter AIDS Cohort study (MACS) and women in the Women’s Interagency HIV Study 
(WIHS). 
 
I. Perform a cross-sectional study using matched samples between males and female serum 
samples to explore differences in HHV-8 titers and infection: 
 
 21 
1. Perform IFA’s on serum samples to determine HHV-8 antibody titers of MACS 
and WIHS study participants. 
2. Examine differences in titer levels based on HIV status, gender, and race. 
 
II. Examine differences in levels of neutralizing antibodies between matched men 
and women. 
 
1. Quantify BAC16 virus stock via a TCID50 assay. 
2. Perform neutralization assays and determine the level of infection by 
the number of cells expressing GFP via flow cytometry 48 hpi. 
 
 
AIM 2: Compare the levels of proinflammatory cytokines between men and women. 
 
 1. Utilize a Meso Scale Discovery (MSD) Proinflammatory Pane V-PLEX 
kit that analyzes serum samples for 10 different human proinflammatory 
cytokines. 
 2. Compare the levels of cytokines between males and females. 
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3.0  MATERIALS AND METHODS 
3.1 CELL LINES 
BCBL-1 cells are a HHV-8 positive, EBV negative B-cell line that originated from a 
pleural effusion lymphoma and were obtained from the NIH AIDS repository (71). BCBL-1’s were 
cultured in RPMI supplemented with 10% fetal bovine serum (FBS), 0.1% Gentamycin, and grown 
at 37C and 5% CO2.  
 
K562 cells originated from a chronic myelogenous erythroleukemia (72). K562-DC-SIGN 
cells were generated by transfecting K562 cells with a plasmid that expresses the DC-SIGN protein 
under the control of the immediate-early CMV promoter (obtained from Ben-Hur Lee- UCLA). 
Transformed cells were selected in media containing 400 μg/mL G418.  K562-DC-SIGN cells 
were constructed by Dr. Heather Hensler in Dr. Jenkins’ laboratory.  Expression of DC-SIGN was 
confirmed by flow cytometry.  K562-DC-SIGN cells were cultured in RPMI supplemented with 
10% fetal bovine serum (FBS), 0.1% Gentamycin, and grown at 37C and 5% CO2. 
 
SLK cells were originally isolated in Israel in 1990 from a tumor biopsy of the oral mucosa 
of an immunosuppressed HIV-1 subject (61). iSLK stands for inducible SLK cells, which are 
induced by doxycycline via the RTA (replication and transcription activator) gene- which controls 
the switch from latency to lytic replication (61, 62). iSLK cells were cultured in DMEM 
supplemented with 10% fetal bovine serum (FBS), 1μg/ml puromycin, 250 μg/ml G418, 1,200 
μg/ml hygromycin B and grown at 37C and 5% CO2. 
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 3.2 SUBJECT SAMPLES 
A total of 249 total subject serum samples were used for this study. 135 male and 114 
female samples. Within the male cohort, there were 47 HIV infected and 88 HIV uninfected 
subjects while within the female cohort, there were 23 HIV infected and 88 HIV uninfected 
subjects the WIHS (Figure 2). 
 
Male samples were obtained from the MACS study, which is an ongoing study of HIV-1 
and AIDS infection in MSM in the United States beginning in 1984.  Participants include HIV 
seropositive and high-risk HIV seronegative subjects. Female samples were obtained from WIHS 
(The Women’s Interagency HIV Study). The WIHS study is an ongoing study of HIV-1 and AIDS 
infection in women, beginning in 1994 and also consists of HIV seropositive and high-risk 
seronegative subjects. Both MACS and WIHS serum samples were matched as closely as possible 
to HIV status, CD4 counts, age, HAART treatment, and race (Figure 3). For the cytokine analysis 
of MACS and WIHS serum samples, only HIV seronegative samples were utilized. This was to 
remove the potential confound of HIV coinfection on proinflammatory cytokine levels in the 
subject groups. Due to the WIHS group only having 23 HIV+ subjects, and the MACS having 47 
HIV+ subjects, there were not enough matching samples, so multiple WIHS samples had to be 
matched to single MACS samples. The MACS and WIHS study protocols were approved by the 
institutional review boards of each of the participating centers, and the University of Pittsburgh. 
Informed consent was obtained from all the men and women. 
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135 subject from the Multicenter Aids Cohort Study (MACS) and 144 subjects from the 
Women’s Interagency HIV Study (WIHS) were used for this study. Out of these male group 47 
subjects were HIV+, and 88 subjects were HIV-, for the female group, 23 subjects were HIV+ and 
88 subjects were HIV-, for a total of 249 total subject samples. WIHS subject samples were tested 
via IFA for HHV-8 seroprevalence by Rebeca Compaore. 
Figure 2 Subject samples from the MACS and WIHS studies. 
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 MACS and WIHS serum samples were matched as closely as possible on factors such as 
age, race, CD4 counts, HIV seropositivity, and HAART status. 
Figure 3 Matched MACS and WIHS subject samples.  
 
3.3 ENHANCED LYTIC IMMUNOFLUORESCENT ASSAY 
HHV-8 antibody titers were determined using an enhanced lytic immunofluorescence 
assay.    The IFA procedure was performed as previously described (Hoffman et al).  Briefly, 
BCBL-1 cells (at a concentration of 2x105 cells/mL) were induced with 20ng per mL TPA (12-O-
tetradecanoylphorbol-13-acetate) for 5 days.  This results in reactivation of latent HHV-8 to a 
productive infection in approximately 15-20% of the cells. The cells were collected, washed with 
1x PBS and fixed in in 4%-paraformaldehyde.  Following fixation, the cells were washed 3 times 
with PBS and permeabilized with 0.05% Triton-X.  The cells were washed twice with PBS, 
resuspended to a concentration of 2 x 107 cells/ml and 2x105 cells (10μL) added to each well on  
a 12-well Teflon coated slide (Fisher Scientific). The cells were allowed to dry at room temperature 
and the slides stored at -20C until use.  
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For the IFA assays, duplicate wells from the 12-well slides were blocked with 20μL 10% 
goat serum at 37C for 1 hour and then treated with the human serum samples for 1 hour at 37C. 
Controls consisted of known positive and negative controls. Subject serum samples were added in 
dilutions ranging from 1:50 – 1:25600. Slides were then washed two times in 1X PBS for 5 minutes 
at room temperature. The secondary antibody (mouse anti-human IgG monoclonal antibody at a 
dilution of 1:200) was added to each of the samples and allowed to incubate at 37C for 1 hour. 
Slides were once again washed two times. Finally, a tertiary FITC-labeled antibody (goat anti-
mouse IGG at a dilution of 1:100) was added to each of the cells, and incubated at 37C for 30 
minutes. Slides were then washed again for 10 minutes in the dark, and stored in the dark until 
visualized via fluorescence microscopy (Figure 4 and 5). 
 
 
Induced BCBL-1 slides were loaded onto 12-well Teflon-coated slides. Human sera 
samples were added to the slides, along with a monoclonal antibody and FITC-labeled tertiary 
antibody to detect HHV-8 lytic proteins. The presence of HHV-8 antibodies is indicated by the 
cells emitting green fluorescence. Photo provided by Dr. Frank Jenkins.  
Figure 4 Positive IFA using BCBL-1 cells and human serum.  
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 A more in-depth look at the IFA experimental design, including BCBL-1 cells induced 
with TPA, dilutions of human sera, monoclonoal anti-human IgG antibody, and a tertiary goat 
anti-mouse IgG FIT-C for detection via fluorescence microscopy. 
Figure 5 Enhanced Lytic Immunofluorescent Assay Experimental Design. 
3.4 BAC16 VIRUS 
The BAC16 GFP virus was introduced into iSLK cells by the J. Jung laboratory, and the 
cells are maintained in 1μg/ml puromycin, 250 μg/ml G418, and 1,200 μg/ml hygromycin B (62). 
The BAC16 virus was isolated from this cell line by inducing the cells with doxycycline (1μg/ml) 
and sodium butyrate (1mM). 4 days after induction, the supernatant was collected and centrifuged 
at 950 x g for 10 minutes at 4C to remove cells and debris. The supernatant was the spun at 25,000 
g for 3 hours in an ultracentrifuge to pellet the virus, and the virus was resuspended in a small 
volume of PBS. 
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 3.5 TCID50 
Levels of infectious BAC16 virus in each viral stock prepared, was determined by a 
TCID50 assay. To perform the TCID50 assay, 4x104 K562-DC-SIGN cells were seeded in a 96 
well U-bottom plate, and dilutions of the virus (10-1 to 10-5) were added to each of the wells (15μL 
of each dilution).  Controls consisted of uninfected wells. Each dilution was placed in 6 replicate 
wells. The plates were incubated at 37C for 48 hours, and then the cells were fixed with 2% 
paraformaldehyde. Detection of GFP expression (due to the BAC156 virus infecting the K562-
DC-SIGN cells) was measured by flow cytometry on an BD Accuri C6 flow cytometer.  The mean 
fluorescence intensity (MFI) of the uninfected cells was averaged and this level + 2 S.D. used as 
the cutoff for positive infection.  An infected well whose MFI was above the cutoff value was 
scored as positive for infection.  The infectious titer was ten calculated using the Reed Muench 
method (75) (Figure 6). 
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 The TCID50 with the harvested BAC16 virus was performed by seeding a 96-well plate 
with 40,000 cells/well of K562 DC-SIGN cells. Serial dilutions of the BAC16 virus were added to 
the plates (6 replicates) in concentrations of 10-1 to 10-5, along with an uninfected control as a 
baseline. The plate was incubated at 37C for 48 hours, and GFP expression was measured via flow 
cytometry. 
Figure 6 TCID50 experimental design. 
 
 
3.6 NEUTRALIZATION ASSAY 
For the neutralization assays, human serum samples at dilutions of 1:10, 1:50, and 1:100 
were added to a known concentration of the virus based on the TCID50 results. This serum/virus 
mixture was incubated for 1 hour at 37C, and each dilution diluted further to concentrations of 10-
1 and 10-2.  The virus/serum samples were added to K562-DC-SIGN cells in 96 well plates(40,000 
cells/well) and incubated at 37C for 48 hours. The cells were fixed with 2% paraformaldehyde and 
analyzed by flow cytometry. The amount of infectious virus in each sample (following 
neutralization) was measured by TCID50 assay (Figure 7).  Neutralization outcome is reported as 
the virus dilution resulting in at least 50% neutralization. 
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 The neutralization assay was completed by adding a known concentration of virus (via the 
TCID50 assay) to various dilutions of human serum samples (1:10, 1:50, and 1:100) along with an 
uninfected control, and a control with no serum added. The virus/serum mixture was incubated at 
37C for 1 hour, and then added to a 96-well plate seeded with K562 DC-SIGN cells at 40,000 
cells/well. The plate was incubated at 37C for 48 hours, and the GFP expression was measured via 
flow. 
Figure 7 Neutralization assay experimental design. 
 
3.7 CYTOKINE ANALYSIS 
To examine levels of proinflammatory cytokines in male and female serum samples, a 
state-of-the-art multiplex ELISA kit was used (Meso Scale Discovery; MSD).  Cytokine levels 
were measured using the MSD 96-well Proinflammatory Panel 1 (human) V-PLEX Kit (Figure 8). 
This assay measures the following cytokines and chemokines: IFN-γ, IL-1β, IL-10, IL-12 p70, IL-
13, IL-2, IL-4, IL-6, IL-8, TNF-α. Each of these cytokines are important in the development of an 
inflammatory response, in immune regulation such as activating adaptive immunity and directing 
a Th1 vs Th2 T-cell response. The MSD assay was performed following the manufacturer’s 
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instructions. The plate was read using an MSD plate reader and levels of the different cytokines 
determined using MSD software. In total, 47 MACS seronegative samples and 25 WIHS 
seronegative samples were tested, in duplicate. Cytokine levels that were below the standard curve 
for that cytokine were given the value of 0 while samples whose levels were above the standard 
curve were given the value of the highest concentration in the standard curve. 
 
 
Diagram of the MSD Proinflammatory cytokine kit. This assay measures levels of 10 of 
the most common proinflammatory cytokines: IFN-γ, IL-1β, IL-10, IL-12 p70, IL-13, IL-2, IL-4, 
IL-6, IL-8, TNF-α. This is done via a sandwich immunoassay, where an electrode is below each 
well on the 96-well plate. A capture antibody is coated on the bottom of the MSD plate, serum 
samples from MCS and WIHS subjects were added, and then the plate was read utilizing a plate 
reader. Obtained from the MSD Proinflammatory cytokine (Human) V-PLEX Kit manual.  
Figure 8 MSD 96-well proinflammatory panel 1 (human) V-PLEX kit. 
 
3.8 DATA ANALYSIS 
SPSS was used to analyze differences between gender, HIV status, and race for the IFA 
antibody titers using non-parametric testing (Independent samples: Mann-Whitney U). SPSS was 
also used to analyze these differences with the MSD proinflammatory cytokine measurements also 
using non-parametric testing (Independent samples: Mann-Whitney U). The distributions 
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examined in the male and female population based on race were also completed using 
nonparametric testing, using the Independent samples- Kruskal-Wallis test. For the correlation 
analysis, a non-parametric Spearman’s rank correlation coefficient was utilized.   
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4.0  RESULTS 
4.1 AIM 1 
4.1.1 Differences in HHV-8 antibody titers between men and women 
HHV-8 antibody titers were determined using the enhanced Lytic IFA assay. This assay 
measures antibodies directed against lytic viral proteins, and an end-point dilution was used to 
determine the antibody titer of each subject: 135 male and 114 female samples (Figure 2). Each 
sample was tested in duplicate and the identity of the samples were blinded to the IFA reader.  
 
As seen in Table 1, the male group had a mean +/- SEM. HHV-8 antibody titer of 1,464 
+/- 4963 and the female group had a mean HHV-8 antibody titer of 1,071 +/- 3811. This represents 
a significant increase in HHV-8 antibody titers among men (n = 135) compared to women (n = 
114; p=0.000). Also seen in Table 1, there was a significant increase in male antibody titers in the 
HIV seropositive groups compared to the women (p = 0.036). However, there was a significant 
increase in female antibody titers in the HIV seronegative group compared to men (p = 0.009). 
There were no significant differences between males or females between HIV+ and HIV+ subjects 
(p = 0.215 and p = 0.217) (Table 1). 
 
Next, differences in antibody titers were examined between races (Caucasians, African 
Americans, and Hispanics) for both male and female subject groups. As seen in Table 2, there 
were no significant differences between antibody titers in any of the three race groups (p = 0.644) 
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in the male study. As seen in Table 3, there were also no significant differences between antibody 
titers in any of the three race groups in the female study.  
 
4.1.2 Neutralization Assay 
The BAC16 virus stock was tested by Dr. Paolo Piazza to determine if the virus was 
successfully able to infect three different cell lines expressing DC-SIGN. This was completed in 
order to determine the most appropriate cell line to complete the neutralization assay experiments 
with. Cells were infected with BAC16 in 100μl total volume in a 96-well plate. The virus was 
removed after 3 hours, and dead cells were excluded by the use of amine binding dies (Aqua from 
Invitrogen). GFP expression was then measured via flow cytometry using a BD LSR FortessaTM 
Cell Analyzer. 
 
Figures 9, 10, and 11, show the infection of three different cell lines expressing DC-SIGN 
with the BAC16 virus at concentrations of 1:0, 1:10, and 1:100: 721.221 DC-SIGN, which is an 
“HLA null” EBV positive B-cell lineage; CHO DC-SIGN, which are Chinese hamster ovary cells; 
and K562 DC-SIGN, which is an erythroleukemia cell line. The results demonstrate that all three 
cell lines were successfully able to be infected by the BAC16 virus. However, the highest levels 
of infection were seen in the K562 DC-SIGN cells (Figure 11). Infection with the BAC16 virus at 
48 hours showed 42.2% of the K562 DC-SIGN cells expressing GFP from the virus.  
 
Figure 12 displays the growth curves of the three cell lines expressing DC-SIGN infected 
with BAC16 from 0 to 72 hpi. The most prolonged level of GFP expression over 48 hours was 
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seen in the K562 DC-SIGN cell line, so this line was chosen for all future experiments. Next, the 
level of DC-SIGN expression on the cells were analyzed via flow using an anti-DC-SIGN 
antibody. This was completed with help by Dr. Paolo Piazza. The percentage of cells expressing 
DC-SIGN, and thus able to be successfully infected by the BAC16 virus, was 81.5% (Figure 13). 
Upon enrichment using an EasyStep anti APC magnetic separation kit (which reduces non-specific 
binding and purifies the cells), the percentage of DC-SIGN positive cells was 98% (Data not 
shown).  In order to keep the amount of BAC16 virus used in each neutralization assay consistent, 
a TCID50 was used to quantify each BAC16 virus harvest. This was completed due to the 
variability in virus concentration for each individual harvest. Typically, the virus concentration 
ranged from 2.5 x 105 – 3.5 x 105 infectious particles/mL. 
 
4.1.3 Examining differences in levels of neutralizing antibodies between matched MACS 
and WIHS samples 
Upon flow cytometry measurement of the percentage of GFP (thus presence of virus) in 
the neutralization assay samples, the results were not what was expected. First, known HHV-8 
seropositive and HHV-8 seronegative serum were used to test the effectiveness of the assay, along 
with uninfected controls containing no BAC16 virus, and another control containing no serum. 
The average percentage of GFP in the uninfected control wells was 0.1%. The average percentage 
of GFP in the wells containing no serum (only BAC16 virus and K562 DC-SIGN cells) was 28.5%. 
The known HHV-8 seropositive serum samples had an average of 0.2% GFP expression. However, 
the known HHV-8 seronegative serum samples had an average of 0.15% GFP expression.  Upon 
discovering this discrepancy, the serum samples were heat inactivated at 56C for 30 minutes to 
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remove any confounding complement, and the neutralization assay was performed again. 
Unfortunately, the results remained the same- extremely low levels of GFP in each sample 
containing serum, regardless of if the serum was HHV-8 seropositive or negative (Table 4). 
 
4.1.4 Summary of Aim 1 
Aim 1 was designed to investigate differences in antibody titers between HIV+ and HIV- 
subject groups in males and females. Upon testing, these results demonstrated that antibody titers 
were significantly higher in the males versus the female population overall (p = 0.00). Male titers 
were also significantly higher in the HIV seropositive group (p = 0.036). Oppositely, female titers 
were significantly higher in the HIV seronegative group versus males (p = 0.009). It was also 
shown that there were no significant differences between males or females between HIV+ and 
HIV+ subjects (p = 0.215 and p = 0.217). Next, xAim 1 examined any possible differences between 
races (Caucasian, African American, and Hispanics) amongst male and female groups. No 
significant differences were found between antibody titers in any races, both in the male and the 
female groups.  
 
The second part of Aim 1 involved investigating differences in neutralizing antibodies 
using the BAC16 virus. The virus was successfully able to infect three different cell lines 
expressing DC-SIGN (721.221 DC-SIGN, CHO DC-SIGN, and K562 DC-SIGN). K562 DC-
SIGN cells showed the most prolonged and consistent level of infection over 48 hours, and were 
utilized for future studies. DC-SIGN expression of this cell line was examined, which showed an 
81.5% expression of DC-SIGN, and then a 98% expression of DC-SIGN upon cell enrichment. 
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The TCID50 to titer the BAC16 virus stock was successful, however due to issues with the 
neutralization assay itself, no further assays were performed, and future work will be conducted in 
our laboratory to determine why these results are occurring. 
 
In Aim 2, we measured the levels of 10 different proinflammatory cytokines in males 
versus females, to determine if males will have an increased level of proinflammatory cytokines 
that coincides with their increased antibody titers overall versus the female group. This may lead 
to their increased rates of reactivation and may also explain why men are at a much greater risk of 
developing KS. 
 
The results in Aim 1 showed that antibody titers in males were significantly higher than 
females overall. In line with these results, levels of proinflammatory cytokines were analyzed 
between male and female populations. It is hypothesized that males, who reactivate more 
frequently than females, will have a higher level of proinflammatory cytokines versus women, 
which has been proven by previous studies to lead to further KS disease progression and 
dissemination of virus throughout the body. 
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4.2 AIM 2 
4.2.1 Analyzing Differences in Proinflammatory Cytokines Between Genders 
For this aim, 47 MACS samples and 25 WIHS samples were examined for their levels of 
proinflammatory cytokines. All of these subject samples were HIV negative, in order to reduce the 
confounding factor of HIV infection on cytokine levels in the serum samples. Upon analysis of the 
MSD cytokine panel, it was discovered that 7 of the 10 cytokines tested were significantly elevated 
in males versus females. These cytokines were: IL-10, IL12p70, IL-1β, IL-2, IL-6, IL-8, and 
TNFα. The average values for each cytokine in the male and female groups, along with standard 
deviations, can be seen in Table 5.  
 
4.2.2 Analyzing Differences in Proinflammatory Cytokines Between Races 
Upon determining that there were significantly higher levels of proinflammatory cytokines 
in males versus females, this study next examined any possible differences between races and 
cytokine levels between three different races: (1) Caucasian, (2) African American, and (3) 
Hispanic.  
Proinflammatory cytokine levels were first examined in the male and female Caucasian 
population only. It was determined that there was a significant difference between male and female 
Caucasians in their levels of IL-6 (p = 0.024) (Table 6). The average values for each cytokine in 
the male and female groups, along with standard deviations for Caucasians only, can also be seen 
in Table 6.  
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 Proinflammatory cytokine levels next were examined in the male and female African 
American population only. It was determined that there was a significant difference between male 
and female African Americans in their levels of IL12p70 (p = 0.030), IL-1β (p = 0.007), IL-2 (p = 
< 0.005), IL-6 (p = < 0.005), IL-8 (p = < 0.005), and TNF-α (p = 0.005) (Table 7). The average 
values for each cytokine in the male and female groups, along with standard deviations for African 
Americans only, can be also seen in Table 7. 
 
Significant differences in cytokine levels were examined in the Hispanic population only. 
It was determine that there was a significant difference between male and female Hispanics in their 
levels of IL-2 (p = 0.002), IL-6 (p = 0.007), and IL-8 (p = 0.001) (Table 8). The average values for 
each cytokine in the male and female groups, along with standard deviations for Hispanics only, 
can also be seen in Table 8.  
 
4.2.3 Analysis of correlation between IFA antibody titers and proinflammatory cytokine 
levels 
Finally, correlations were examined between IFA titers and the 10 proinflammatory 
cytokines studied in Aim 2. This analysis was used to determine if antibody titers had any effect 
on proinflammatory cytokine production, or if any proinflammatory cytokines had a positive or 
negative correlation with one another. The analyses were broken down into 3 groups (1) HIV SN 
MACS + WIHS cohorts together (Table 9), (2) HIV SN MACS (Table 10), and (3) HIV SN WIHS 
(Table 11). In the first group, including both men and women, there were no significant differences 
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between any of the cytokines. There were also no differences in the second group (MACS HIV 
SN), although IL-2 had a p value of 0.05. In the final group, HIV SN WIHS, IL-12p70 was 
significantly different- meaning that there was a positive correlation between IFA titer and IL12-
p70 in the women.  
 
4.2.4 Summary of Aim 2 
Interestingly, 7 out of the 10 proinflammatory cytokines examined in the MSD panel were 
significantly elevated in total males versus females (IL-10, IL12p70, IL-1β, IL-2, IL-6, IL-8, and 
TNFα). In the Caucasian population, 1 proinflammatory cytokine (IL-6) was significantly higher 
in males versus females. In the African American population, 6 proinflammatory cytokines were 
significantly higher in the male population (IL12p70, IL-1β, IL-2, IL-6, IL-8, and TNF-α) Finally, 
in the Hispanic group, 3 proinflammatory cytokines (IL-2, IL-6, and IL-8) were significantly 
higher in the male population versus the female. These results overall and between Caucasians, 
African Americans, and Hispanics show that males have significantly higher levels of 
proinflammatory cytokines versus women in the HIV seronegative population.  No strong 
correlations were seen when examining IFA titers and proinflammatory cytokines, except in the 
HIV SN WIHS group, where IL-12p70 was seen to be positively correlated to an increase in 
antibody titer.  
 
 41 
Table 1 MACS and WIHS antibody titers +/- SEM for HIV seropositive and HIV 
seronegative groups. 
 
Antibody titers were measured using an enhanced lytic immunofluorescent assay and end-
point dilution. 
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Table 2 MACS antibody titers +/- SEM by race. 
 
Antibody titers were measured using an enhanced lytic immunofluorescent assay and an 
end-point dilution on Caucasian, African American, and Hispanic HIV seronegative men. 
 
 
Table 3 WIHS antibody titers +/- SEM by race. 
 
Antibody titers were measured using an enhanced lytic immunofluorescent assay and an 
end-point dilution on Caucasian, African American, and Hispanic HIV seronegative women. 
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 Infection of 721.221 DC-SIGN cells with BAC16 virus. 721.221 DC-SIGN cells are an 
HLA null EBV positive B-cell lineage. This line was able to be infected by the BAC16 virus at 
concentrations of 1:0, 1:10, and 1:100. Provided by Dr. Paolo Piazza. 
Figure 9 BAC16 virus infection of 721.221 DC-SIGN cells. 
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Infection of CHO DC-SIGN cells with the BAC16 virus. CHO DC-SIGN cells are Chinese 
hamster ovary cells. This line was able to be infected by the BAC16 virus at concentrations of 1:0, 
1:10, and 1:100. Provided by Dr. Paolo Piazza. 
Figure 10 BAC16 virus infection of CHO DC-SIGN cells. 
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Infection of K562 DC-SIGN cells with BAC16 virus. K562 DC-SIGN cells are an 
erythroleukemia cell line. This line was able to be infected by the BAC16 virus at concentrations 
of 1:0, 1:10, and 1:100, and showed the highest level of infection at 48 hours. This was the cell 
line chosen to perform the TCID50 and neutralization assays using the BAC16 virus. Provided by 
Dr. Paolo Piazza. 
Figure 11 BAC16 virus infection of K562 DC-SIGN cells. 
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72-hour growth curve with 721.221 DC-SIGN cells, CHO DC-SIGN cells, and K562 DC-
SIGN cells, measuring the percentage of GFP expressing cells (BAC16 infected cells). 721.221 
and CHO DC-SIGN cells peak at 24 hours, while K562 DC-SIGN cells peak at 48 hours, and have 
the highest and most consistent level of infect. Provided by Dr. Paolo Piazza. 
Figure 12 Growth curve of cell lines expressing DC-SIGN infected with BAC16. 
 
 
Expression of DC-SIGN was measured in K562 DC-SIGN cells using an anti DC-SIGN 
antibody. 81.5% of the K562 DC-SIGN cells were expressing DC-SIGN at this time, before 
enrichment. Post-enrichment, the percentage of DC-SIGN positive cells was 98% (Data not 
shown). Provided by Dr. Paolo Piazza. 
Figure 13 DC-SIGN expression of K562 DC-SIGN cells. 
 47 
Table 4 Neutralization Assay Results.  
 
 
Dilutions of HHV-8 seropositive and HHV-8 seronegative serum samples added to an 
exact concentration of the BAC16 virus, and incubated with K562 DC-SIGN cells at 37C for 48 
hours. The plates were then subsequently measured for GFP via fluorescence microscopy. 
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Table 5 MSD proinflammatory cytokine V-PLEX panel (MACS vs. WIHS total). 
 
Results of the MSD panel examining 10 proinflammatory cytokines between all HIV 
seronegative males and females. Significant differences demonstrate an significant increase in 
proinflammatory cytokines in males versus females. 
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Table 6 MSD proinflammatory cytokine V-PLEX panel (MACS vs. WIHS 
Caucasian). 
 
Results of the MSD panel examining 10 proinflammatory cytokines between Caucasian 
HIV seronegative males and females. Significant differences demonstrate an significant increase 
in proinflammatory cytokines in males versus females. 
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Table 7 MSD proinflammatory cytokine V-PLEX panel (MACS vs. WIHS African 
American). 
 
Results of the MSD panel examining 10 proinflammatory cytokines between African 
American HIV seronegative males and females. Significant differences demonstrate an significant 
increase in proinflammatory cytokines in males versus females. 
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Table 8 MSD proinflammatory cytokine V-PLEX panel (MACS vs. WIHS Hispanic). 
 
Results of the MSD panel examining 10 proinflammatory cytokines between Hispanic HIV 
seronegative males and females. Significant differences demonstrate an significant increase in 
proinflammatory cytokines in males versus females. 
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Table 9 Total HIV SN MACS and WIHS HHV-8 antibody titer and proinflammatory 
cytokine correlation. 
 
 
The total number of MACS and WIHS HIV seronegative serum samples were compared 
using both their HHV-8 viral titers from the IFA results in Aim 1, to the proinflammatory cytokine 
analysis in Aim 2 using a Pearson’s correlation coefficient to determine possible positive and 
negative associations between titers and cytokine levels.  
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Table 10 HIV SN MACS HHV-8 antibody titer and proinflammatory cytokine correlation. 
 
The total number of WIHS HIV seronegative serum samples were compared using both 
their HHV-8 viral titers from the IFA results in Aim 1, to the proinflammatory cytokine analysis 
in Aim 2 using a Pearson’s correlation coefficient to determine possible positive and negative 
associations between titers and cytokine levels.  
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Table 11 HIV SN WIHS HHV-8 antibody titer and proinflammatory cytokine correlation. 
 
The total number of MACS HIV seronegative serum samples were compared using both 
their HHV-8 viral titers from the IFA results in Aim 1, to the proinflammatory cytokine analysis 
in Aim 2 using a Pearson’s correlation coefficient to determine possible positive and negative 
associations between titers and cytokine levels.  
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5.0  DISCUSSION 
KS was first described in 1872 as an “indolent tumor” in elderly Mediterranean men (6). 
Over 100 years later, HHV-8 was discovered as the etiologic agent of KS (4, 12). Since the initial 
description of AIDS in the early 1980’s, KS is the most common AIDS-associated malignancy 
(31). Though much has been discovered about the virus in the past several decades (presentation 
of the virus, transmission, immune evasion strategies, etc.) there is still much to be learned about 
the development of KS in different populations, particularly men versus women (6, 12, 13, 74). 
The prevalence of KS is not evenly distributed throughout the population (13, 20). Though both 
females and males both are infected with HHV-8, KS is seen mainly in the male population, at a 
rate of roughly 13:1 versus females. 
 
In this study, two hypotheses were generated to explain why there is such a strong sexual 
bias in KS development. The first possibility as to why men develop KS more often than women, 
is a more robust humoral response in women, which would result in a reduced incidence of KS. 
This suggests that women may have higher antibody titers compared to their male counterparts, 
leading to a more robust humoral immune response. This may possibly suppress KS reactivation 
in females.  
 
The second hypothesis is hormonal control, which may limit viral transcription replication 
of HHV-8, resulting in lower antibody titers in females, and a reduced incidence of KS. 
Specifically, estrogen may be controlling or preventing reactivation in women. Previous research 
in our laboratory has established compelling evidence that estrogen plays an important role in 
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HHV-8 infection by showing that ERE’s in the HHV-8 genome can modulate gene transcription, 
and that estrogen can induce the transcription of HHV-8 genes. These data emphasizes the 
importance of estrogen in controlling varying aspects of HHV-8 pathogenesis and gene 
transcription. For this reason, males would have higher antibody titers compared to women, who 
may have decreased or suppressed viral transcription due to estrogen. Along with this hypothesis, 
we predicted that due to males developing KS more frequently than females, they would have 
increased levels of proinflammatory cytokines versus women, as many proinflammatory cytokines 
can actually assist in HHV-8 infection and disease progression. 
 
The present study was completed to analyze these two hypotheses between males versus 
females who are infected with HHV-8, and to determine which is the most logical to explain the 
KS gender bias. This study provides an important step in determining why women do not develop 
KS as often as men do, and understanding this gender bias could possibly lead to more effective 
treatments or preventative therapies for the development of KS. 
 
First, this study analyzed differences in antibody titers between males and females. This 
was competed via an enhanced lytic immunofluorescent assay (IFA) on 135 male and 114 female 
samples (Figure 2). These samples were matched as closely as possible on factors such as HIV 
status, CD4+ T-cell counts, race, age, etc. (Figure 3). The IFA’s were completing using the BCBL-
1 cell line, which is latently infected with HHV-8 (Figures 4 and 5). It was found that the male 
group had a significantly higher mean antibody titer versus women (1,464 vs. 1,071). 
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However, antibody titers between HIV+ and HIV- men and women significantly differed. 
In the HIV seropositive group, male titers were significantly higher than the female group. In the 
HIV seronegative group, female titers were significantly higher than the male group (Table 1). 
These results suggest that there may be another factor which is causing females to mount a stronger 
immune response to HHV-8 in the HIV seronegative group. It is also noted that there is no 
significant difference in antibody titers in males or females between genders (Tables 2 and 3). 
 
There are several possible hypotheses as to why antibody titers in females are higher in the 
HIV- group, and male antibody titers are higher in the HIV+ group. Some of these factors include 
the timeline of infection- whether HIV infection or HHV-8 infection occurred first. For example, 
if a female would become infected with HIV first, and subsequently infected with HHV-8, the 
female would likely have a decreased T-cell count that may attribute to a decreased immune 
response to HHV-8 (31). This may explain why women have a significantly lower HHV-8 titer in 
the HIV seropositive group, and a significantly higher titer in the HIV seronegative group. It could 
also be suggested that the women in the WIHS study had become infected with HIV before 
becoming infected with HHV-8.  Alternatively, the MACS study group contains many men with 
extremely “high risk” sexual lifestyles. This behavior may also suggest increased exposures to 
HHV-8 over time, meaning multiple exposures to the virus, possibly increasing a male’s chance 
of reactivation over time. Overall, these serological results demonstrate that males are mounting a 
stronger humoral response compared to women, which leads us to believe that the second 
hypothesis, hormonal control, may be responsible for the gender bias associated with KS 
development.  
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This study next examined neutralizing antibodies between males versus females. 
Neutralizing antibodies are an important component of the immune response against viral 
infection, but their role in KS infection has not been studied in depth (57). They have been 
implicated in the control of many diseases, included several herpesvirus-associated diseases. There 
have been several previous studies that have detected the presence of neutralizing antibodies in 
HHV-8 infected subjects. First, Wood et al. found that KS subjects had a higher level of nAb 
versus those who had not yet developed KS. Second, Kimball et al. demonstrated that HHV-8 
infection was able to be inhibited by nAb in seropositive subject samples, and this effect was not 
seen in seronegative subjects. To date, no group has utilized flow cytometry to examine 
neutralizing antibody levels within HHV-8 infected subjects. 
 
The neutralization assay was completed using a GFP-expressing BAC16 virus, and was 
subsequently infected by Dr. Paolo Piazza into three different cell lines that express DC-SIGN. 
The K562 DC-SIGN cell line was chosen as the optimal line for our neutralization assays (Figures 
9, 10, 11, and 12). These cells were enriched to increase the percentage of expression of DC-SIGN, 
thus increasing the chances of viral infection. The virus was tittered via a TCID50 assay, and then 
the neutralization assay was completed on known HHV-8 + and known HHV-8 – samples. The 
samples were analyzed via flow cytometry for the level of GFP remaining in each well. A lower 
level of GFP corresponded to a lower concentration of virus in the sample, thus a higher level of 
neutralizing antibodies in the subject serum. 
 
Unfortunately, the results from the neutralization assays were inconclusive. Upon flow 
cytometry measurement of GFP expression, the average percentage of GFP in the uninfected 
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control wells was 0.1%. The average percentage of GFP in the wells containing no serum (only 
BAC16 virus and K562 DC-SIGN cells) was 28.5%. The known HHV-8 seropositive serum 
samples had an average of 0.2% GFP expression. All three of these experimental groups were as 
to be expected, but unfortunately the GFP expression percentage in the HHV-8 seronegative 
sample was 0.15%. Because this subject was not infected with HHV-8, they should have no 
antibodies specific for HHV-8. For this reason, the negative sample should not be neutralizing any 
of the BAC16 virus in culture. This leads us to believe that there is some component of the serum 
itself and the BAC16 virus that is either killing the harvested virus, or neutralizing the virus via an 
alternative mechanism. Originally, we suspected it might be due to the complement cascade killing 
the virus, but even after heat inactivating the serum, almost no virus was present in the HHV-8 
seronegative samples again. 
 
To further examine our second hypothesis, this study then examined the levels of 10 
proinflammatory cytokines to determine if we would observe differences between males and 
females. It is hypothesized that men, who reactivate more frequently and have been shown to have 
overall higher antibody titers, will have higher levels of proinflammatory cytokines in their serum. 
It has been demonstrated in previous studies that proinflammatory cytokines can increase disease 
progression of HHV-8, and development of KS. This may explain why men are at a greater risk of 
developing KS versus women. Because KS is an inflammatory cytokine mediated disease, the 
induction of inflammation is an essential component of disease development and progression (68). 
Previous research by Jenkins et al. demonstrated that HHV-8 infection triggers the release of 
proinflammatory cytokines, specifically IL-6, IL-8, and TNF-α (66). For our study, only HIV 
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seronegative subjects were examined for proinflammatory cytokines, as HIV is a potential 
confound when examining inflammation in HHV-8 infected subjects. 
 
Upon MSD analysis, it was determined that 7 of the 10 cytokines tested were significantly 
elevated in the male population: IL-10, IL12p70, IL-1β, IL-2, IL-6, IL-8, and TNFα (Tables 4). 
More specifically, in the Caucasian male population, IL-6 was significantly higher in males 
(Tables 5) In the African American population, IL-1β, IL-2, IL-6, IL-8, and TNF-α were all 
significantly higher in males (Table 7). Finally, in the Hispanic population, IL-2, IL-6, and IL-8 
were all significantly higher in males (Table 8). 
 
There were three cytokines that were not significantly different between males and females 
in any of the groups. These are IFN-γ, IL-4, and IL-13. IFN-γ. IFN-γ is crucial and necessary for 
innate and adaptive immunity against many types of pathogens- viral, bacterial, etc. Thus, it is 
possible to suggest that males and females will not differ significantly in their levels of IFN-γ, as 
it is such an important component of our immune system as a whole. The other two cytokines 
which did not differ between genders are IL-4 and IL-13, both which behave similarly in that they 
drive the immune system towards a Th2 response versus a Th1 response. Th1 cells produce 
proinflammatory cytokines, which would kill viruses like HHV-8 (68). So, it could be concluded 
that both males and females appear to be both favoring a Th1 response, in an attempt to combat 
HHV-8 infection. 
 
The proinflammatory cytokines significantly upregulated in males: IL-10, IL12p70, IL-1β, 
IL-2, IL-6, IL-8, and TNFα, each have their own inflammatory effects on the immune system. 
 61 
First, IL-10 is an anti-inflammatory cytokine that actually downregulates Th1 immune responses 
(68). Downregulation of the Th1 immune response could have implications towards HHV-8 
infection, both positively and negatively. Positively, it could be the body’s attempt to reduce 
inflammation, which is being brought on via HHV-8 infection. Negatively, it could be a 
mechanism of HHV-8 to downregulate cytokines like IFN-γ, which are critical to a healthy 
immune system, and would aid in combatting infection. IL-10 is the only cytokine out of the 7 
mentioned above that has anti-inflammatory effects on the body (68). 
 
The next cytokine that is upregulated in males is IL-12p70, which favors the generation of 
Th1 cells, and promotes cytolytic activity. IL-1β promotes inflammation by activating 
lymphocytes, and produces prostaglandins, which has the ability to induce fevers.  IL-2 stimulates 
the proliferation and growth of T-cells. IL-6 is a B-cell stimulatory factor, and a CTL 
differentiation factor, which is extremely important in inducing inflammation and apoptosis in 
humans (63). IL-8 induces chemotaxis, and causes cells to migrate towards sites of infection, thus 
highly associated with inflammation and angiogenesis (64). Finally, TNFα is also highly involved 
in regulating other immune cells, and can induce apoptosis, inflammation, and also has the ability 
to inhibit tumor growth and viral replication (67). It also stimulates IL-1 production (66). 
 
All of these results demonstrate several possible conclusions. First, it is clear that men are 
eliciting a stronger humoral response to HHV-8 versus women- both overall and in the HIV+ 
group. However, women’s titers were significantly higher in the HIV- group. This may have to do 
with the timecourse of infection, multiple exposures to HHV-8, etc. But this will need to be 
examined in more depth in future studies. In general, male antibody titers were significantly higher 
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than women’s titers, which coincides with our second hypothesis, that men will have increased 
HHV-8 antibody titers, coinciding with an increase in proinflammatory cytokines. Along with this, 
women will have decreased antibody titers due to a possible role of estrogen in suppressing 
reactivation and development of KS.  
 
Because of this, we examined whether men would have an increased proinflammatory 
cytokine response to HHV-8 versus women, which can cause damage to the body and actually 
enhance KS disease progression. From our data, it is clear that men are mounting a stronger 
proinflammatory response to HHV-8 infection versus women- both generally, and also between 
races. Jenkins et al. previously reported that IL-6, IL-8, and TNF-α were increased after HHV-8 
infection, and were able to alter the maturation of immune cells (66). These cytokines were also 
shown to be associated with lytic viral replication. Many of these cytokines favor cytolytic activity, 
apoptosis, and chemotaxis (64, 67). Others are B-cell stimulators that may ultimately aid in 
disseminating infection within the infected host (66). This is due to the fact that HHV-8 targets B-
cells for infection and replication, to produce more infectious virus. However, both the males and 
females are infected with HHV-8 in this cytokine analysis, and both are mounting an immune 
response to the virus. These results do not mean that women are not producing these cytokines, 
simply that males are producing these proinflammatory cytokines in greater concentrations, which 
appears to have a positive effect on disease progression, which may be why men develop KS more 
frequently than women. 
 
Finally, we examined the correlation between HHV-8 IFA titers and proinflammatory 
cytokine levels in both the male and female groups (Figures 9, 10, and 11). Using only the HIV 
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seronegative samples for comparison, 3 groups were tested: (1) Both MACS and WIHS HIV SN 
cohorts together, (2) MACS HIV SN, and (3) WIHS HIV SN. In the first group analyzing both 
cohorts, there were no significant differences in cytokine levels based on HHV-8 antibody titer. 
This was also observed in the MACS group as well. In the WIHS group, however, IL-12p70 was 
significantly different (p = 0.041) and a correlation coefficient of 0.411, meaning there is a positive 
correlation between a higher HHV-8 antibody titer in women, and an increase in IL-12p70. This 
data demonstrates that the higher HHV-8 antibody titers in the male group does not correlate with 
higher proinflammatory cytokine levels. In women, a positive correlation was seen with 1 out of 
the 10 cytokines tested. This leads us to believe that the HHV-8 antibody titer is not what is driving 
the proinflammatory cytokine response. This means that the higher the titer a patient has does not 
mean they will have higher levels of proinflammatory cytokines. 
 
5.2 PUBLIC HEALTH SIGNIFICANCE 
 
Identifying the differences in antibody titers between different subject groups has not been 
investigated in the context of males versus females at this level. The results of this study play an 
important role in understanding the result of HHV-8 infection and possible KS development. These 
results will hopefully aid those in the future by examining other mechanisms that may be important 
in KS development- whether it may be disease progression, or disease suppression. Identifying 
that our first hypothesis, that women will have a more robust overall humoral response, was 
rejected. However, our second hypothesis, that men will generally have higher antibody titers and 
proinflammatory cytokines, which will ultimately lead to KS, was supported. This is an important 
step in understanding KS development and disease progression. Particularly due to the fact that 
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men are producing much higher amounts of several cytokines versus females, though both are 
infected with HHV-8. In the future, this information could help researchers and physicians 
understand mechanisms behind disease development, and may be able to use this information to 
suppress or decrease the chances of reactivation in subject groups.  
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6.0  FUTURE DIRECTIONS 
Upcoming studies should be focused on two particular components:  
 
(1) Examining the neutralization assay further. It is clear that there is some component in 
the human serum samples we have obtained, or possibly the viral harvest, that is interfering with 
the quantification of BAC16 virus, even in the HHV-8 negative samples. I also believe it would 
be important to perform a longitudinal study on the serological samples, with much more 
information about times of infection, reactivation events, etc. by having multiple blood samples. 
This would allow us to examine the relationship between HIV and HHV-8 more closely as well.  
 
(2) Examining hormonal control, specifically estrogen. The completed aims from our 
second hypothesis were supported: That men will elicit a stronger immune response to HHV-8, 
resulting in higher viral antibody titers and an increased level of proinflammatory cytokines. The 
next logical step would be to examine sex hormones and estrogen in more depth, by determining 
their methods of possibly limiting viral transcription and replication, or exactly how it may be 
suppressing disease progression in females. Previous research in our laboratory has shown that 
ERE’s are able to control HHV-8 transcription, but the exact mechanisms and effects of this control 
should be examined in more depth. It would be essential to examine exactly how estrogen can be 
controlling or suppressing KS reactivation in women.  
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